Seminars in arthritis and rheumatism最新文献

{"title":"Measurement properties of the decisional conflict scale in people living with chronic non-cancer pain: a secondary analysis of the DECIDE-PAIN pan-Canadian survey.","authors":"Florian Naye, Maxime Sasseville, Karine Toupin-April, France Légaré, Marie-Pierre Gagnon, Chloé Cachinho, Thomas Gérard, Valentin Vaillant, Olivia Dubois, Alison M Hoens, Yannick Tousignant-Laflamme, Simon Décary","doi":"10.1016/j.semarthrit.2025.152842","DOIUrl":"https://doi.org/10.1016/j.semarthrit.2025.152842","url":null,"abstract":"<p><strong>Objectives: </strong>The Decisional Conflict Scale is a candidate instrument for the Core Outcome Measurement Set of the OMERACT Shared Decision-Making working group. However, its validity among chronic non-cancer pain populations is lacking. We explored measurement properties of the English version of the 16-item Decisional Conflict Scale in this population.</p><p><strong>Methods: </strong>Informed by the COnsensus-based Standards for the selection of health status Measurement INstruments guidelines, we conducted a secondary analysis of a panCanadian cross-sectional survey. We assessed the distribution of score including ceiling and floor effects, readability, internal consistency, structural validity of an hypothesized five-factor model, and convergent and discriminant validities. We tested measurement invariances regarding age, sex, health literacy, and education.</p><p><strong>Results: </strong>We collected data from 1103 respondents. We found ceiling effect at the item-level, while no ceiling and floor effects at the subscale and total score levels. Readability scores were below the sixth-grade reading level. All results of internal consistency were above the a priori threshold. The confirmatory factorial analysis resulted in a good model fit. We found good convergent, but poor discriminant validities. We confirmed measurement invariances for age, sex, health literacy, and education.</p><p><strong>Conclusion: </strong>This secondary analysis of a panCanadian survey provides evidence of the measurement properties of the Decisional Conflict Scale in people living with chronic non-cancer pain. We propose that this instrument should be analyzed using its total score rather than its subscales due to a lack of discriminant validity. Further research is necessary to enhance its validity, possibly by re-examining its factor structure.</p>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"75 ","pages":"152842"},"PeriodicalIF":4.4,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive impairment and other neuropsychiatric manifestations in patients with primary vasculitis: a systematic review.","authors":"Ruo Yan Chen, Jennifer Mandzia, Lillian Barra","doi":"10.1016/j.semarthrit.2025.152806","DOIUrl":"10.1016/j.semarthrit.2025.152806","url":null,"abstract":"<p><strong>Background: </strong>Vasculitis is an autoimmune disorder causing blood vessel inflammation, potentially affecting the central nervous system. This review explores neuropsychiatric manifestations with a focus on cognitive impairment in patients with vasculitis.</p><p><strong>Methods: </strong>Embase, PubMed, Scopus, and PsycINFO were searched up to December 31^st, 2023, for studies of primary vasculitis reporting on cognitive impairment. Case reports, reviews, and case series with <5 patients were excluded. Study quality was evaluated using the Newcastle Ottawa Scale.</p><p><strong>Results: </strong>From the 4,249 identified studies, 43 met the inclusion criteria, comprising 1,216 cases of PCNSV, 481 of ANCA-associated vasculitis (AAV), 151 of giant cell arteritis (GCA), 28 of Takayasu arteritis (TAK), 22 of polyarteritis nodosa (PAN), 32 of Behçet's disease (BD), and 54 of other vasculitis types. Patients' ages ranged from 7.1-75.6 years and 11-100 % were female. Most studies were single-center retrospective studies of good or fair quality. Cognitive impairment was noted in 275/750 (11-62 %) of adult-onset PCNSV, 126/433 (10-54 %) of childhood-onset PCNSV, 62/157 (12-61 %) of AAV, 4/12 (20-43 %) of GCA, and 261/486 (20-67 %) of other vasculitis cases. Standardized neuropsychological testing was done in 12/43 (28 %) of studies. A minority of studies investigated factors associated with neuropsychiatric manifestations or response to treatment. These studies reported associations with MRI abnormalities and with worse prognosis and/or higher disease activity. Most patients were reported to improve after immunosuppressive therapy but have residual neuropsychiatric symptoms.</p><p><strong>Conclusions: </strong>Cognitive impairment and other neuropsychiatric manifestations are commonly reported in vasculitis, highlighting the need for routine neuropsychological assessments.</p>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"152806"},"PeriodicalIF":4.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive analysis of disease activity, neuropsychiatric symptoms, imaging features and risk factors for seizure in hospitalized patients with juvenile-onset neuropsychiatric systemic lupus erythematosus.","authors":"Yufen Tang, Peng Huang, Jie Xu, Lingjuan Liu, Xiaochuan Wu, Yan Cao, Xiqiang Dang, Lu Zhang, Zhou She, Senlin Luo, Hong Peng, Yuqiong Chen, Jinwen Luo, Wangxin Duan, Xiaojie He, Fang Yuan, Dingan Mao, Liqun Liu","doi":"10.1016/j.semarthrit.2025.152798","DOIUrl":"10.1016/j.semarthrit.2025.152798","url":null,"abstract":"<p><strong>Background: </strong>Neuropsychiatric systemic lupus erythematosus (NPSLE) is a common complication of juvenile systemic lupus erythematosus, with high morbidity and lethality rates. This study aimed to comprehensively analyze the clinical characteristics and related influencing factors of NPSLE, providing important basis for the early detection and early diagnosis of NPSLE.</p><p><strong>Methods: </strong>The clinical data of juvenile-onset NPSLE patients, juvenile non-NPSLE patients, and adult-onset NPSLE patients admitted to the Xiangya Second Hospital of Central South University from January 2010 to December 2023 were retrospectively analyzed. The data of the juvenile-onset NPSLE patients were divided into subgroups via a cluster analysis. Drawing upon retrospective clinical data and case reports from databases, a thorough synthesis of the characteristics of Juvenile-onset NPSLE cases presenting with seizures was presented. Multivariate logistic regression analysis was utilized to assess influencing factors of juvenile-onset NPSLE with seizures.</p><p><strong>Results: </strong>A total of 89 juvenile-onset NPSLE patients, 219 juvenile-onset non-NPSLE patients, and 150 adult-onset NPSLE patients were included. Compared to non-NPSLE patients, juvenile-onset NPSLE patients showed higher rates of myositis, cardiac involvement, overlap syndrome, anti-SSA antibodies and ANCA positivity, as well as higher disease activity scores. Individuals with juvenile-onset NPSLE exhibited a greater likelihood of headaches, seizures, and movement disorders and renal involvement, positive rates of anti-dsDNA and anti-nucleosome antibodies, and disease activity scores, while displaying a lower probability of polyneuropathy in comparison to adult patients. Disease activity emerged as an independent risk factor for seizures.</p><p><strong>Conclusion: </strong>These findings contribute to the early detection of potential NPSLE patients and help clinicians to pay attention to potentially high-risk populations for NPSLE.</p>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"152798"},"PeriodicalIF":4.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world persistence of urate-lowering therapy following a treat-to-target intervention: A two-year follow-up analysis of the STOP gout trial.","authors":"Samantha Kohn, Harlan Sayles, Lindsay N Helget, Bryant R England, Punyasha Roul, Jeff A Newcomb, Bridget Kramer, Anne Davis-Karim, Mary T Brophy, Ryan Ferguson, Michael H Pillinger, Tuhina Neogi, Paul M Palevsky, Hongsheng Wu, James R O'Dell, Ted R Mikuls","doi":"10.1016/j.semarthrit.2025.152800","DOIUrl":"10.1016/j.semarthrit.2025.152800","url":null,"abstract":"<p><strong>Objective: </strong>Though gout guidelines endorse treat-to-target urate-lowering therapy (ULT), its long-term durability following treat-to-target implementation has not been extensively studied. Examining follow-up data from a trial implementing treat-to-target management, we evaluated the frequency and determinants of ULT persistence.</p><p><strong>Methods: </strong>This analysis examined participants completing the 72-week STOP Gout trial with available follow-up data extending 2-years post-study. Participants were followed passively using administrative and electronic health record data with persistence defined by a ULT dispensing episode overlapping with the 2-year post-study time point. Associations of participant factors with ULT persistence were examined using multivariable logistic regression.</p><p><strong>Results: </strong>Participants in this analysis (n = 638) were predominantly male (99 %) and had a mean age of 62.7 years. At 2-years post-study, 66 % continued ULT. Adjusting for covariates, ≥2 rheumatology visits post-study (vs. none) was associated with greater ULT persistence (aOR 1.75; 95 % CI 1.13-2.72). ULT persistence was lower in individuals reporting Black/African American race (aOR 0.56; 95 % CI 0.36-0.87), Hispanic ethnicity (aOR 0.21; 95 % CI 0.09-0.50), and better quality-of-life at the beginning of post-study follow-up. Though not reaching significance, achievement of serum urate goal at 48-weeks during STOP Gout study demonstrated a borderline association with greater long-term persistence (aOR 1.68; 95 % CI 0.99-2.85).</p><p><strong>Conclusion: </strong>Though interventions implementing treat-to-target ULT have demonstrated efficacy in trials, this study suggests that such interventions may have limited durability following transitions back to real-world gout management. The issue of limited treatment durability appears to be compounded among underrepresented patient populations and improved in the context of ongoing rheumatological care.</p>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"152800"},"PeriodicalIF":4.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative evaluation of clinical efficacy and safety of uric acid-lowering drugs: A modeling analysis of literature aggregate data.","authors":"Zihao Cai, Yinghua Lv, Yuan Liu, Xiaoya Chen, Xiao Yang, Aobo Feng, Jiesen Yu, Lujin Li, Qingshan Zheng","doi":"10.1016/j.semarthrit.2025.152801","DOIUrl":"10.1016/j.semarthrit.2025.152801","url":null,"abstract":"<p><strong>Objective: </strong>To quantitatively assess and compare the efficacy and safety characteristics of different urate-lowering drugs, focusing on their dosage, formulation, and effects in various populations, in order to support and optimize current urate-lowering treatment strategies.</p><p><strong>Methods: </strong>Clinical trials on urate-lowering drug treatments for hyperuricemia or gout were retrieved from PubMed, Embase, and Cochrane Library databases from the inception of the database until May 26, 2024. A model-based meta-analysis (MBMA) was conducted to quantitatively analyze the time effects of serum uric acid reduction rates and gout attack rates following urate-lowering drug interventions, along with their influencing factors. Additionally, a single-arm meta-analysis was performed to summarize the proportion of patients achieving serum uric acid levels below 6 mg/dl, estimated glomerular filtration rate (eGFR), adverse events (AEs), serious adverse events (SAEs) and dropout rate. Subgroup analyses were conducted to compare the efficacy and safety characteristics of urate-lowering drugs across different dosages, formulations, and populations.</p><p><strong>Results: </strong>A total of 49 studies involving 10,591 participants were included, assessing nine drugs across three categories: xanthine oxidase inhibitor (XOI), Urate transporter 1 inhibitor (URAT1), and Urate oxidase (URICASE). Results indicated that after three months, uric acid levels decreased by 35.4 %, 37.5 %, and 79.6 % for XOI, URAT1, and URICASE, respectively, with efficacy platforms reached at weeks 7, 10, and immediately. Within three months of intervention, the gout attack rates for XOI and URICASE were 18.9 % and 51.2 %, respectively; after one year, these rates decreased to 7.4 % and 13.3 %. The changes in eGFR after one year of intervention were 0.7 % for XOI and -2.5 % for URAT1. In terms of safety, the incidence rates of AEs were 55.8 %, 51.8 %, and 92.4 % for XOI, URAT1, and URICASE, respectively, while the SAEs were 4 %, 2.4 %, and 18.8 %. Patient compliance was described in terms of dropout rates, which were 17 %, 8 % and 31 % for XOI, URAT1 and URICASE, respectively. Subgroup analyses revealed a clear dose-response relationship for the urate-lowering effects of XOI and URAT1, with flexible dosing showing superior efficacy compared to fixed dosing, and sustained-release formulations outperforming immediate-release formulations. However, higher doses were associated with an increased rate of gout attacks.</p><p><strong>Conclusion: </strong>This study provides a comprehensive quantitative analysis of the efficacy and safety characteristics of urate-lowering drugs, offering important evidence for optimizing treatment strategies for gout and hyperuricemia.</p>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"152801"},"PeriodicalIF":4.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144804743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of sex and systemic inflammation in the development of cardiovascular disease in osteoarthritis: A population-based cohort study using the CLSA.","authors":"Anthony V Perruccio, Caitlin Kral, Calvin Yip, Lihi Eder, J Denise Power, Mayilee Canizares, Jessica M Wilfong, George Heckman, Elizabeth Badley","doi":"10.1016/j.semarthrit.2025.152804","DOIUrl":"10.1016/j.semarthrit.2025.152804","url":null,"abstract":"<p><strong>Objective: </strong>Cardiovascular disease (CVD) is increased in osteoarthritis (OA), particularly in females. This longitudinal, population-based study investigated CVD development in OA vs. no-OA. We hypothesized a) having OA confers an additional risk beyond the Framingham Risk Score (FRS), and b) systemic inflammation contributes to the OA-CVD link, and to a greater extent in females.</p><p><strong>Methods: </strong>Data: Canadian Longitudinal Study on Aging cycles 1-3 (6 years of follow-up). Respondents completed questionnaires and provided blood samples. Individuals with OA were age-sex-matched to individuals without OA. Baseline FRS-risk (largely reflecting metabolic factors) and a systemic inflammation variable (comprising four factors) were derived. Cox regressions examined time-to-CVD for OA vs. non-OA, exploring the roles of FRS and systemic inflammation, adjusting for sociodemographics, comorbidities, physical activity, and BMI.</p><p><strong>Results: </strong>Sample: 2123 individuals with, 2123 without OA. CVD incidence/10,000 person-years: 123.0 and 65.0 in females (p = 0.008), 187.6 and 166.4 in males (p = 0.670), with and without OA. Model results: Among females only, OA was associated with increased CVD risk (HR=1.78 (1.22, 2.58)). FRS-risk distribution was similar for OA and non-OA, and 'high-risk' FRS was similarly associated with CVD development for both sexes. In females only, OA was associated with higher systemic inflammation, and higher systemic inflammation with increased CVD risk (HR=1.77 (1.02, 3.05)).</p><p><strong>Conclusions: </strong>CVD risk in females with OA is underestimated by the FRS, an algorithm often used in clinical settings. While increased systemic inflammation, a potential intervention target, contributes to the OA-CVD link in females, there remains still unexplained increased CVD risk in OA.</p>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"152804"},"PeriodicalIF":4.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144804744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A clue for subclinical CNO in adolescents with acne conglobata and hidradenitis suppurativa: Persistan acute phase rectans elevation.","authors":"Veysel Cam, Yağmur Bayindir, Ahmet Cevdet Ceylan","doi":"10.1016/j.semarthrit.2025.152803","DOIUrl":"10.1016/j.semarthrit.2025.152803","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"152803"},"PeriodicalIF":4.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Letter to \"Pathological contributors to organ damage and mortality in systemic sclerosis: A nationwide matched case-control study\": Author's Reply.","authors":"Jessica L Fairley, Laura Ross, Elizabeth Paratz, Penelope McKelvie, Andre La Gerche, Mandana Nikpour","doi":"10.1016/j.semarthrit.2025.152840","DOIUrl":"https://doi.org/10.1016/j.semarthrit.2025.152840","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"75 ","pages":"152840"},"PeriodicalIF":4.4,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145245122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to “pathological contributors to organ damage and mortality in systemic sclerosis: a nationwide matched case-control study”","authors":"Dr. Parth Aphale ,&nbsp;Shashank Dokania ,&nbsp;Himanshu Shekhar","doi":"10.1016/j.semarthrit.2025.152839","DOIUrl":"10.1016/j.semarthrit.2025.152839","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"75 ","pages":"Article 152839"},"PeriodicalIF":4.4,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145200919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response: Does baseline nephrotic range proteinuria determine the long-term outcomes of membranous lupus nephritis patients? Reply Letter to Capuano et al. (Letter to the Editor: Voclosporin in Late Onset Lupus Nephritis with Anti-PLA2R Antibodies)","authors":"Fadi Kharouf ,&nbsp;Pankti Mehta ,&nbsp;Virginia Carrizo Abarza ,&nbsp;Dafna D Gladman ,&nbsp;Laura P Whittall Garcia ,&nbsp;Zahi Touma","doi":"10.1016/j.semarthrit.2025.152836","DOIUrl":"10.1016/j.semarthrit.2025.152836","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"75 ","pages":"Article 152836"},"PeriodicalIF":4.4,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145200885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}